OptimizeRx Corporation reports developments in healthcare technology for life sciences marketing, with updates centered on tools that connect pharmaceutical brands with healthcare professionals and patients. The company’s platform uses EHR-based access, omnichannel activation, the Dynamic Audience Activation Platform, and Micro-Neighborhood audiences to support HCP and direct-to-consumer engagement.
Recurring OptimizeRx news includes product and network launches, programmatic access to EHR advertising, privacy-safe identity resolution collaborations, quarterly and annual results, debt and share-repurchase actions, and board or leadership changes. Coverage also reflects the company’s focus on privacy-compliant audience targeting and campaign measurement across healthcare marketing channels.
OptimizeRx (Nasdaq: OPRX) announced four new partner agreements on Dec. 17, 2025 that expand its point-of-care (POC) network, deepen exclusivity with key platforms, and increase total National Provider Identifier reach. Together the additions and renewals raise OptimizeRx’s unique NPI reach by 37%.
Key deals include an exclusive multi-year agreement with a high-demand e-prescribing platform, a new point-of-discharge partnership that extends access when treatment plans are finalized, and multi-year renewals with two top-performing EHR/eRx partners that secure premium inventory and greater visibility into future channel revenue.
OptimizeRx (Nasdaq: OPRX) reported third-quarter 2025 results showing continued revenue and profitability growth. Q3 revenue was $26.1 million (+22% YoY) and gross profit was $17.5 million (+30% YoY). GAAP net income was $0.8 million ($0.04 per share) versus a loss in prior-year Q3; non-GAAP net income was $3.9 million ($0.20 per diluted share). Adjusted EBITDA rose to $5.1 million. Cash and short-term investments totaled $19.5 million at September 30, 2025. The company raised FY2025 guidance to $105–$109M revenue and $16–$19M adjusted EBITDA, and introduced FY2026 guidance of $118–$124M revenue and $19–$22M adjusted EBITDA.
OptimizeRx (Nasdaq: OPRX) will hold a conference call to discuss second quarter results for the period ended June 30, 2025. The call is scheduled for Thursday, August 7, 2025 at 4:30 p.m. ET (1:30 p.m. PT); a press release with financial results will be issued prior to the call.
Dial-in details include toll-free 1-844-825-9789, international 1-412-317-5180 and Conference ID 10200608. A webcast and a Call Me™ option are available. A replay will be available for 12 months via the company Investors page at http://www.optimizerx.com/investors.
OptimizeRx (Nasdaq: OPRX) will hold a third quarter 2025 conference call on Thursday, November 6, 2025 at 4:30 p.m. ET to discuss results for the quarter ended September 30, 2025. Management will host the call, followed by Q&A. Financial results will be released in a press release prior to the call.
Call access includes toll-free and international numbers, a Call Me link and a live webcast; a replay will be available for 12 months on the company investor website.
OptimizeRx (NASDAQ:OPRX), a healthcare technology solutions provider specializing in connecting life sciences companies with healthcare professionals and patients, has announced its participation in the 9th Annual Lake Street Capital Best Ideas Growth Conference. The event is scheduled for September 11, 2025, in New York, NY.
The company's management team will be available for meetings with institutional investors during the conference. Interested parties should contact their institutional representatives to arrange meetings.
OptimizeRx (NASDAQ: OPRX) has announced a strategic partnership with Lamar Advertising Company (NASDAQ: LAMR) to transform healthcare out-of-home (OOH) advertising. The collaboration integrates OptimizeRx's patented Micro-Neighborhood® Targeting (MNT) data with Lamar's nationwide advertising inventory, enabling precise targeting of healthcare audiences at the ZIP+4 level.
The partnership allows pharmaceutical and healthcare brands to leverage disease prevalence data for targeted OOH campaigns while maintaining privacy compliance. Key benefits include granular clinical geographic targeting, cost-effective scale compared to linear TV, nationwide reach across Lamar's network, measurable results, and strategic media mix integration.
OptimizeRx (NASDAQ:OPRX), a healthcare technology solutions provider, has announced significant leadership team advancements to accelerate its Rule of 40 strategy, which focuses on balancing growth with increased profitability.
Key appointments include: Ed Stelmakh as Chief Financial & Strategic Officer, Theresa Greco continuing as Chief Commercial Officer, Marion Odence-Ford as Chief Legal & Administrative Officer, Doug Besch as Chief Product & Technology Officer, Brendan Merrell as Chief Operating Officer, and Andy D'Silva as Chief Business Officer.
Under CEO Steve Silvestro's leadership, these organizational changes aim to enhance execution speed, strategic clarity, and drive the company's goal of achieving Rule of 40 in the next 2-3 years while transitioning to a recurring revenue model.
OptimizeRx (NASDAQ:OPRX) reported strong Q2 2025 financial results, with revenue increasing 55% year-over-year to $29.2 million. The company achieved significant improvements in profitability, posting a GAAP net income of $1.5 million ($0.08 per share) compared to a loss of $4.0 million in Q2 2024.
Gross profit rose 59% to $18.6 million, while Adjusted EBITDA reached $5.8 million, up from $0.5 million year-over-year. The company strengthened its financial position by paying down $4.5 million of principal on its outstanding term loan, $4.0 million above schedule.
Based on strong performance, OptimizeRx raised its full-year 2025 guidance, now expecting revenue between $104-108 million and Adjusted EBITDA between $14.5-17.5 million.
Paynela, an AI-driven healthcare financing company, has appointed William Febbo to its Board of Directors. Febbo, the former CEO of OptimizeRX (NASDAQ: OPRX) from 2016 to 2025, brings over 30 years of healthcare technology experience to the role.
During his tenure at OptimizeRX, Febbo transformed the company into a comprehensive omnichannel platform serving top pharmaceutical companies. He currently serves as Office of the Chairman at Oxbridge Health and on the Board of Directors at LifeMD. The appointment comes as Paynela, recently named a 2024 AWS Generative AI Trailblazer, has achieved a 320x increase in processing speed through its AI-driven healthcare data review platform.
OptimizeRx (NASDAQ: OPRX), a healthcare technology solutions provider, has appointed CEO Steve Silvestro to its Board of Directors, effective June 20, 2025. Silvestro, who joined the company in 2019, has served as CEO since March 2025, following his interim CEO role from January 2025.
Under Silvestro's leadership, the company has made significant progress in strengthening its market position. His strategic focus includes enhancing customer experiences, deepening pharmaceutical partnerships, transitioning to a recurring revenue model, and advancing toward Rule of 40 performance. Board Chairperson Lynn Vos expressed confidence in Silvestro's leadership and the company's foundation for long-term value creation.